GMAB News and Press, Genmab A/S From 09/13/21

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For September

Media Release Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL) published in The Lancet Results als...

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet - Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary...

Bolt has built out a next-generation immunotherapy platform to design biologics for cancers that are not accessible for the current standard-of-care. The company's lead asset, BDC-1001, is expected to complete phase 1 clinical trials later this year creating a window for an opportunis...

Genmab currently has aided and/or partnered in the development of four FDA approved monoclonal antibody therapies. While not the owners, developers, or manufacturers of most of these therapies, the company earns money via licensing of their novel and innovative technology. This wi...

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q2 2021 Earnings Call Aug 11, 2021 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q2 2021 Earnings Call Transcript

Genmab A/S (GMAB) Q2 2021 Results Conference Call August 11, 2021 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Tahi Ahmadi - Chief Medical Officer Conference Call Participants Wim...

The following slide deck was published by Genmab A/S in conjunction with their 2021 Q2 earnings call. For further details see: Genmab A/S 2021 Q2 - Results - Earnings Call Presentation

BMEZ is a fund focused on the growth side of healthcare, with exposure to some private investments. Private investments can be quite lucrative as it is participating before public launches that can see shares rise spectacularly. On the other side of this large potential is a highe...

Biotech companies have experienced exponential growth over the past year owing to their contribution to efforts to combat the COVID-19 pandemic. The rising demand for medicines and therapies for treating several other critical diseases and significant breakthroughs in developing customized dr...